We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Inappropriate Laboratory Testing Found Throughout Medicine

By LabMedica International staff writers
Posted on 02 Dec 2013
Print article
Laboratory testing is the single highest-volume medical activity and drives clinical decision-making across medicine with over five billion tests performed each year in the USA.

The overall landscape of inappropriate testing, which is thought to be dominated by repeat testing, is unclear. Systematic differences in initial versus repeat testing, measurement criteria, and other factors would suggest new priorities for improving laboratory testing.

Scientists at the Harvard Medical School (Boston, MA, USA) and colleagues from Beth Israel Deaconess Medical Center (BIDMC; Boston MA, USA) performed a multi-database systematic review on published studies from 1997–2012. For measures of overutilization, they determined whether the inappropriateness criteria were objective or subjective; restrictive, permissive, or both; and whether they involved initial testing, repeat testing, or both. Test volume, low, medium, or high was also determined.

From these measurements, they set about estimating the overall prevalence of inappropriate testing, including overuse, tests that are ordered but not indicated, and underuse tests that are indicated but not ordered. They also distinguished between inappropriate initial testing, during a clinician's first evaluation of a patient or in response to new signs or symptoms, and inappropriate repeat testing, which occurs when the same tests are repeated, often multiple times, during a patient's hospitalization.

The authors found that not only was there a 30% overall rate of test overuse, there was a similar rate of underuse. On average, the available evidence suggests that underutilization is more prevalent than overutilization, 44.8% versus 20.6%. Ramy Arnaout, MD, DPhil, the senior author, said, “It's not ordering more tests or fewer tests that we should be aiming for, it's ordering the right tests, however few or many that is. Remember, laboratory tests are inexpensive. Ordering one more test or one less test isn't going to ‘bend the curve,’ even if we do it across the board. It's everything that happens next: the downstream visits, the surgeries, the hospital stays that matters to patients and to the economy and should matter to us.”

William Taylor, MD, a clinician in BIDMC's Division of General Medicine and Primary Care, said, “Because laboratory tests play such a crucial and ubiquitous role in medicine, efforts to identify opportunities for improvement in the selection of tests have the potential to contribute greatly to the care patients receive. By drawing attention to this important topic, the authors are setting the stage for further work to help more patients benefit from proper test selection, while protecting patients from the potential harm and wasted resources induced by unnecessary tests.” The study was published on November 15, 2013, in the journal Public Library of Science ONE.

Related Links:

Harvard Medical School
Beth Israel Deaconess Medical Center 


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
H.pylori Test
Humasis H.pylori Card

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.